Drug-eluting stents: results, promises and problems

In-stent restenosis is the major drawback of percutaneous coronary interventions, occurring in 10–40% of the patients. Recently, new stents have emerged which are loaded with anti-inflammatory, anti-migratory, anti-proliferative or pro-healing drugs. These drugs are supposed to inhibit inflammation and neointimal growth and subsequently in-stent restenosis. In this review article the results of human clinical studies investigating drug-eluting stents are discussed from a clinical point of view, focussing on the efficacy in the prevention of restenosis and their potential side effects.
Both success and failure in the field of drug-eluting stents have been described. Successful devices are the sirolimus-eluting and the polymer-based paclitaxel-eluting stents. Potentially dangerous side effects of drug-eluting stents are adverse drug interactions, incomplete stent apposition and increased in-stent thrombosis rates. Demonstration of long-term efficacy is mandatory since in some animal studies a delayed healing has been observed. Currently, the successful drug-eluting stents are under investigation in all types of lesions.
We conclude that the results with some drug-eluting stents are promising, but further evidence on long-term efficacy and safety, also in high-risk subgroups, is needed.
Author Keywords: Drug-eluting stents; Restenosis; Side effects; Sirolimus; Paclitaxel

Department of Cardiology C5-P, Leiden University Medical Center, Albinusdreef 2, PO Box 9600, 2300 RC, Leiden, The Netherlandsb TNO Prevention and Health, Gaubius Laboratory, Leiden, The Netherlands
read on: International Journal of Cardiology Volume 99, Issue 1


Popular posts from this blog

Inflammatory Bowel Disease an Independent Risk Factor for MI

Inflamation and Alzheimer disease

The Council of the European Union has decided that the European Medicines Agency (EMA) will be relocated to the City of Amsterdam.